The treatment of kidney disease requires lifestyle interventions (such as implementing physical activity [34,35,36], improving diet habits with a low-protein diet [37,38,39,40,41], and limited salt intake [42,43]), and the optimization of hypertensive and diabetes care (such as the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with and without diabetes [44,45,46,47,48,49], mineralocorticoid receptor antagonist (MRA) [50,51], and glucagon-like peptide-1 receptor agonists (GLP-1 RA) in adults with type 2 diabetes [52]). The gene discussed is SLC5A2; the disease is kidney disorder.